Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, confirmed that Sandoz Tyruko (natalizumab-sztn) is now available to patients in the United States.  Tyruko is the first and only FDA-approved biosimilar of natalizumab to treat relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease.  Tyruko will be commercialized in the U.S. by its collaboration partner Sandoz,...